Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. more
Time Frame | VCEL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.51% | -3.39% | 0.2% |
1-Month Return | 7.18% | -1.92% | 2.72% |
3-Month Return | 27.91% | -10.54% | 7.31% |
6-Month Return | 35.91% | -4.47% | 10.44% |
1-Year Return | 65.37% | 4.06% | 27.53% |
3-Year Return | 38.88% | 0.94% | 30.88% |
5-Year Return | 223.76% | 36.67% | 89.21% |
10-Year Return | 1871.83% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 117.85M | 124.18M | 156.18M | 164.37M | 197.52M | [{"date":"2019-12-31","value":59.67,"profit":true},{"date":"2020-12-31","value":62.87,"profit":true},{"date":"2021-12-31","value":79.07,"profit":true},{"date":"2022-12-31","value":83.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 37.57M | 39.95M | 50.16M | 54.58M | 61.94M | [{"date":"2019-12-31","value":60.66,"profit":true},{"date":"2020-12-31","value":64.5,"profit":true},{"date":"2021-12-31","value":80.98,"profit":true},{"date":"2022-12-31","value":88.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 80.28M | 84.23M | 106.03M | 109.79M | 135.58M | [{"date":"2019-12-31","value":59.21,"profit":true},{"date":"2020-12-31","value":62.13,"profit":true},{"date":"2021-12-31","value":78.2,"profit":true},{"date":"2022-12-31","value":80.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 68.12% | 67.83% | 67.88% | 66.80% | 68.64% | [{"date":"2019-12-31","value":99.24,"profit":true},{"date":"2020-12-31","value":98.82,"profit":true},{"date":"2021-12-31","value":98.9,"profit":true},{"date":"2022-12-31","value":97.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 91.53M | 81.86M | 113.88M | 126.85M | 142.04M | [{"date":"2019-12-31","value":64.44,"profit":true},{"date":"2020-12-31","value":57.63,"profit":true},{"date":"2021-12-31","value":80.17,"profit":true},{"date":"2022-12-31","value":89.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (11.25M) | 667.00K | (7.85M) | (17.06M) | (6.46M) | [{"date":"2019-12-31","value":-1686.81,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1177.51,"profit":false},{"date":"2022-12-31","value":-2557.42,"profit":false},{"date":"2023-12-31","value":-969.12,"profit":false}] |
Total Non-Operating Income/Expense | 3.19M | 1.36M | 492.00K | 2.04M | 7.39M | [{"date":"2019-12-31","value":43.21,"profit":true},{"date":"2020-12-31","value":18.37,"profit":true},{"date":"2021-12-31","value":6.66,"profit":true},{"date":"2022-12-31","value":27.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (9.66M) | 3.04M | (7.58M) | (15.99M) | (2.37M) | [{"date":"2019-12-31","value":-317.51,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-249.08,"profit":false},{"date":"2022-12-31","value":-525.23,"profit":false},{"date":"2023-12-31","value":-77.79,"profit":false}] |
Income Taxes | (1.76M) | 180.00K | (111.00K) | 721.00K | 814.00K | [{"date":"2019-12-31","value":-215.72,"profit":false},{"date":"2020-12-31","value":22.11,"profit":true},{"date":"2021-12-31","value":-13.64,"profit":false},{"date":"2022-12-31","value":88.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (7.91M) | 2.86M | (7.47M) | (16.71M) | (3.18M) | [{"date":"2019-12-31","value":-276.15,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-260.86,"profit":false},{"date":"2022-12-31","value":-583.41,"profit":false},{"date":"2023-12-31","value":-111.1,"profit":false}] |
Income From Continuous Operations | (9.66M) | 2.86M | (7.47M) | (16.71M) | (10.25M) | [{"date":"2019-12-31","value":-337.47,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-260.86,"profit":false},{"date":"2022-12-31","value":-583.41,"profit":false},{"date":"2023-12-31","value":-358,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.91M) | 2.86M | (7.47M) | (16.71M) | (3.18M) | [{"date":"2019-12-31","value":-276.15,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-260.86,"profit":false},{"date":"2022-12-31","value":-583.41,"profit":false},{"date":"2023-12-31","value":-111.1,"profit":false}] |
EPS (Diluted) | 0.15 | 0.05 | (0.17) | (0.36) | (0.09) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":33.33,"profit":true},{"date":"2021-12-31","value":-113.33,"profit":false},{"date":"2022-12-31","value":-240,"profit":false},{"date":"2023-12-31","value":-60,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VCEL | |
---|---|
Cash Ratio | 2.46 |
Current Ratio | 4.61 |
Quick Ratio | 4.23 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VCEL | |
---|---|
ROA (LTM) | -0.22% |
ROE (LTM) | 1.54% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VCEL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VCEL | |
---|---|
Trailing PE | 705.75 |
Forward PE | 106.38 |
P/S (TTM) | 12.29 |
P/B | 10.82 |
Price/FCF | NM |
EV/R | 12.27 |
EV/Ebitda | 266.52 |
PEG | NM |
Vericel Corp Ord (VCEL) share price today is $56.321
Yes, Indians can buy shares of Vericel Corp Ord (VCEL) on Vested. To buy Vericel Corp Ord from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VCEL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vericel Corp Ord (VCEL) via the Vested app. You can start investing in Vericel Corp Ord (VCEL) with a minimum investment of $1.
You can invest in shares of Vericel Corp Ord (VCEL) via Vested in three simple steps:
The 52-week high price of Vericel Corp Ord (VCEL) is $61.49. The 52-week low price of Vericel Corp Ord (VCEL) is $32.31.
The price-to-earnings (P/E) ratio of Vericel Corp Ord (VCEL) is 705.75
The price-to-book (P/B) ratio of Vericel Corp Ord (VCEL) is 10.82
The dividend yield of Vericel Corp Ord (VCEL) is 0.00%
The market capitalization of Vericel Corp Ord (VCEL) is $2.79B
The stock symbol (or ticker) of Vericel Corp Ord is VCEL